Publication:
BRCA2 and Other DDR Genes in Prostate Cancer.

dc.contributor.authorNombela, Paz
dc.contributor.authorLozano, Rebeca
dc.contributor.authorAytes, Alvaro
dc.contributor.authorMateo, Joaquin
dc.contributor.authorOlmos, David
dc.contributor.authorCastro, Elena
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderEuropean Association of Urology Research Foundation
dc.contributor.funderDepartment of Defense Award
dc.contributor.funderFundacion BBVA
dc.contributor.funderCERCA Program/Generalitat de Catalunya
dc.contributor.funderFEDER funds/European Regional Development Fund
dc.date.accessioned2023-01-25T13:32:08Z
dc.date.available2023-01-25T13:32:08Z
dc.date.issued2019-03-12
dc.description.abstractGermline and somatic aberrations in DNA damage repair (DDR) genes are more prevalent in prostate cancer than previously recognized, with BRCA2 as the most commonly altered gene. Germline mutations in BRCA2 have been linked to poor prognosis when patients are managed under the protocols currently approved for prostate cancer. The impact of germline mutations in other DDR genes beyond BRCA2 remain unclear. Importantly, a quarter of prostate cancer patients identified as germline mutation carriers lack a family history of cancer. The clinical implications of somatic DDR defects are yet to be elucidated. Poly ADP-ribose polymerase (PARP) inhibitors and platinum-based chemotherapy have proven to be effective in the treatment of other tumor types linked to BRCA1 and BRCA2 alterations and several trials are currently evaluating their efficacy in prostate cancer. Here, we summarize the available evidence regarding the prevalence of somatic and germline DDR defects in prostate cancer; their association with clinical outcomes; the trials assessing the efficacy of new therapies that exploit DDR defects in prostate cancer and briefly discuss some uncertainties about the most appropriate management for these patients.
dc.description.sponsorshipR.L., A.A., and D.O. were funded by the Instituto de Salud Carlos III (grants CM17/00221 to R.L., PI16/01070 and CP15/00090 to A.A., and PI16/01565 to D.O.). A.A. is supported by grants from the European Association of Urology Research Foundation (EAURF/407003/XH), a Department of Defense Award (W81XWH-18-1-0193), Fundacion BBVA, CERCA Program/Generalitat de Catalunya, and FEDER funds/European Regional Development Fund (ERDF)-A Way to Build Europe. D.O. was funded by grants from the Ministerio de Economía y Empresa (RYC-2015-18625). E.C. and J.M. were supported by Young Investigator Awards from the Prostate Cancer Foundation. J.M. and D.O. were supported by an Impact Award from the Department of Defense US (PC170510P2).
dc.description.version
dc.identifier.citationNombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E. BRCA2 and Other DDR Genes in Prostate Cancer. Cancers (Basel). 2019;11(3):352. Published 2019 Mar 12.
dc.identifier.doi10.3390/cancers11030352
dc.identifier.issn2072-6694
dc.identifier.pmcPMC6468860
dc.identifier.pmid30871108
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468860/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6694/11/3/352/pdf?version=1552404625
dc.identifier.urihttp://hdl.handle.net/10668/13709
dc.issue.number3
dc.journal.titleCancers
dc.journal.titleabbreviationCancers (Basel)
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number15
dc.provenanceRealizada curación de contenido 23/06/2025
dc.publisherMdpi
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.relation.projectIDCM17/00221
dc.relation.projectIDPI16/01070
dc.relation.projectIDCP15/00090
dc.relation.projectIDPI16/01565
dc.relation.projectIDEAURF/407003/XH
dc.relation.projectIDW81XWH-18-1-0193
dc.relation.projectIDRYC-2015-18625
dc.relation.projectIDPC170510P2
dc.relation.publisherversionhttps://www.mdpi.com/426574
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBRCA2
dc.subjectDDR
dc.subjectDNA damage and repair
dc.subjectPARP inhibitors
dc.subjectprostate cancer
dc.subject.decsNeoplasias de la Próstata
dc.subject.decsGenes BRCA2
dc.subject.decsGenes BRCA1
dc.subject.decsReparación del Daño del ADN
dc.subject.decsInhibidores de PARP
dc.subject.decsQuimioterapia con Platino
dc.subject.meshGerm-Line Mutation
dc.subject.meshPoly(ADP-ribose) Polymerase Inhibitors
dc.subject.meshPlatinum
dc.subject.meshProstatic Neoplasms
dc.subject.meshDNA Damage
dc.subject.meshGerm Cells
dc.titleBRCA2 and Other DDR Genes in Prostate Cancer.
dc.typereview
dc.type.hasVersionVoR
dc.volume.number11
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC6468860.pdf
Size:
252.71 KB
Format:
Adobe Portable Document Format